FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukaemia By Ogkologos - November 26, 2024 601 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ASC4FIRST study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS... November 15, 2024 Men’s skin cancer rates increase by 50% over decade June 24, 2021 Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... January 13, 2022 Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS... July 7, 2025 Load more HOT NEWS Woman with Breast Cancer May Have Saved Her Twin’s Life by... Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45... Durable Responses Observed in Patients with Papillary Craniopharyngiomas Tested Positive for... Cancer in My Community: Developing Pediatric Palliative and Supportive Care in...
